BTX earnings call for the period ending March 31, 2019.
News & Analysis: BioTime
The small-cap biopharma company issued a simple reminder to investors.
Let’s take a look at three reasons Geron bounced back more than 200% in 2013, and how its industry peers -- Celgene, Novartis, and Incyte -- have been affected.
Continuing our countdown of the very worst healthcare stocks of 2012, BioTime comes in at No. 20.
Geron announces that its selling its stem cell assets, but the deal isn't finalized yet.
BioTime's proposal for Geron's stem cell program will benefit shareholders more than the company.
These stocks just took off, but are they about to make a return trip to Earth?
Folks in the know think these stocks will rise. Should you join them?
A light R&D budget, a technology that may not be commercially viable, and a stock prone to promotion make one investor skeptical of BioTime's prospects.